We propose to use the CARRA Registry to understand patterns by which children and youth with well-controlled juvenile arthritis taper or stop adalimumab (such as Humira, Amjevita, or other brands). We will also use Registry data to understand what happens to children and youth after tapering or stopping compared with children and youth who continue adalimumab. We will compare quality of life, rates and timing of flare and, for those with flares, how quickly those flares are controlled. This study will help prepare for a future, more definitive randomized clinical trial on tapering or stopping adalimumab among children and youth with well-controlled juvenile arthritis.